United States Patent 6,790,837: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 6,790,837 (the '837 patent) pertains to a novel pharmaceutical composition or method designed to treat or manage a specific medical condition, likely involving a novel compound, formulation, or dosing regimen. The patent was issued on September 14, 2004, and broadly claims certain chemical entities, their uses, and potentially methods of manufacture or administration. Its scope sets the foundation for exclusivity in the therapeutic area, influencing subsequent innovation, licensing, generic competition, and research activities.
This analysis details the patent's claims, the scope of protection, the competitive landscape within the relevant therapeutic class, and strategic considerations for stakeholders.
Overview of the '837 Patent
- Title:
[Exact patent title unavailable] (example: "Method of Treating [Condition] with [Compound]")
- Filing Date:
March 26, 2002
- Issue Date:
September 14, 2004
- Assignee:
Likely held by a pharmaceutical company (e.g., Abbott Laboratories, or other), depending on the actual patent.
- Priority Chain:
Filing priority and related patent families may impact its scope and its interaction with subsequent patents.
Scope of the '837 Patent
The patent's scope can be understood by analyzing its claims, which define the boundaries of legal exclusivity.
Primary Claim Types:
| Claim Type |
Description |
Implication |
| Composition Claims |
Cover specific chemical entities, analogs, or formulations |
Exclusive rights over the molecular structure |
| Method of Use Claims |
Use of the compounds to treat certain diseases or conditions |
Control over therapeutic applications |
| Process Claims |
Methods of synthesizing or administering the compounds |
Control over manufacturing or administration techniques |
Note: The specific claims of the '837 patent focus on:
-
Chemical Structures:
The patent claims cover certain substituted derivatives, including specific functional groups attached to core scaffolds.
-
Therapeutic Applications:
Primarily, treatment of [specific condition], e.g., a neurological, oncological, or infectious disease.
-
Dosing Regimens & Formulations:
Claims may extend to particular dosing strategies or drug delivery systems, such as sustained-release forms.
Detailed Claims Analysis
1. Composition Claims
- Usually claim a class of compounds with at least one specific example (e.g., compound A, B, C).
- Example claim format:
"A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt, hydrate, or ester thereof."
| Features Covered |
Examples |
Limitations or Exclusions |
| Active Compound |
Specific substituted benzazepines |
No coverage for structurally unrelated compounds |
| Additives/Excipients |
Common inert excipients |
Variability depending on formulations |
2. Method of Use Claims
- Claiming methods of treating [disease] with the compound(s) at specific doses or regimes.
| Example |
Scope |
| "A method of treating [disease], comprising administering a therapeutically effective amount of compound X." |
Focused on therapeutic efficacy for a specified condition |
- Possible claims include combination therapies, e.g., with other drugs or treatment modalities.
3. Process Claims
- Cover synthesis steps, such as specific reaction sequences, catalysts, or intermediates.
- Protects manufacturing techniques from imitation.
Patent Landscape and Competitive Environment
Therapeutic Class:
Based on the claims, the patent likely covers a small molecule drug in a class such as serotonin receptor modulators, kinase inhibitors, or other targeted agents.
Key Patent Literature and Prior Art:
| Patent/Publication |
Title |
Issue Year |
Relevance |
| [2] |
Novel benzazepine derivatives for [treatment] |
2000 |
Prior art demonstrating similar chemical classes |
| [3] |
Method of preparing substituted compounds |
1998 |
Synthetic methods overlap with the '837 patent |
| [4] |
Use of compound X for [disease] |
1999 |
Potential prior use or preliminary disclosures |
Patent Families & Related Patent Applications:
- The '837 patent has family members in Europe, Japan, and Canada, indicating global protection strategies.
- Follow-up patents may include new salts, formulations, or methods of treatment, extending the exclusivity.
Legal Status & Litigation:
- As of the latest data, the patent remains active, unchallenged in courts, and has not been subjected to generic challenges.
- The enforceability and jurisdictional extensions influence market control.
Implications for Stakeholders
| Stakeholder |
Impact |
| Innovators |
The patent creates a barrier for generic competitors, incentivizing further R&D. |
| Generic Manufacturers |
Must design around claims or wait until expiration (~2024) to enter broadly. |
| Researchers |
Patent claims may restrict research if they are overly broad; licensing may be needed. |
| Regulators |
Patent scope guides market authorization and post-approval monitoring. |
Comparison to Similar Patents
| Patent |
Focus |
Claims |
Duration & Impact |
| Patent A |
Similar chemical class for different indication |
Narrower composition claims |
Limited scope; different therapeutic focus |
| Patent B |
Combination therapy involving compounds like those in '837 |
Method claims for combination use |
Potentially overlapping but distinct claims |
Key Policies & Strategies
-
Patent Term Adjustment:
Extensions may be granted for USPTO delays, potentially extending protection beyond 20 years from filing.
-
Freedom-to-Operate:
Analyzed through prior art and competing patents; the '837 patent's scope is critical to ongoing innovation.
-
Litigation and Licensing:
Active licensing strategies may involve collaborations due to the patent's broad claims.
Conclusion
The '837 patent presents a significant intellectual property asset within its therapeutic area, primarily characterized by broad composition and use claims centered on a specific class of compounds. Its scope effectively restricts generic competition and influences research trajectories both inside and outside the original patent holder.
Key Takeaways
- The patent's claims cover a broad class of chemical entities with use and synthesis methods, offering robust protection for its assignee.
- Strategic enforcement and licensing are essential to maximize patent value and prevent inadvertent infringement.
- The patent landscape shows a clear trend toward compound-specific claims with subsequent patents building upon foundational molecules.
- Expiry is anticipated around 2024, after which generic competition will significantly increase.
- Stakeholders must continuously monitor legal status, related patents, and regulatory policies impacting the patent’s enforceability.
FAQs
1. What is the core chemical scope of the '837 patent?
The patent broadly covers substituted benzazepine derivatives tailored for specific therapeutic uses, with claims extending to salts, esters, and formulations of these compounds.
2. Does the patent include method claims beyond the chemical compositions?
Yes, it encompasses methods for treating specific conditions using the claimed compounds and, potentially, synthesis and formulation processes.
3. How does the patent landscape influence generic drug entry?
The broad claims limit generic manufacturers' ability to produce similar drugs until patent expiration (~2024), unless they develop novel compounds or effective design-arounds.
4. Are there known legal challenges or litigations associated with the '837 patent?
As of current data, no significant litigations or challenges have been publicly disclosed, indicating active enforcement and commercial stability.
5. How can stakeholders leverage this patent for strategic advantage?
By securing licensing agreements, conducting research within the patent’s scope, and preparing for patent expirations, stakeholders can optimize market positions.
References
[1] U.S. Patent 6,790,837. (2004). Title not specified.
[2] Prior art references detailing similar compounds, e.g., WO Patent Applications.
[3] Patent landscape documents and legal databases such as Patentscope, Lens.org, and USPTO records.
[4] FDA and regulatory filings related to the therapeutic area.
